Tick-borne Encephalitis Clinical Trial
Official title:
Tick-borne Encephalitis Virus Research in Limousin
Cases of encephalitis of varying severity have been described in recent years in eastern France involving tick-borne encephalitis virus (TBEV). The main objective is to demonstrate the presence of TBEV in Limousin, in patients with a positive Lyme serology, or a neurological picture compatible with TBEV.
Cases of encephalitis of varying severity have been described in recent years in eastern France involving tick-borne encephalitis virus (TBEV). The epidemiological situation in France is poorly known with about 20 cases diagnosed per year, mainly in Alsace and Haute-Savoie. The infection can result in fever and an influenza-like picture, which can be complicated by encephalitis-like neurological disorders, or even death. TBEV is transmitted by the tick Ixodes ricinus, which also carries Borrelia burgdorferi, the agent of Lyme disease. Limousin is one of the French regions with the highest prevalence of Lyme disease. These ticks can harbor various pathogens, including TBEV. A case was described in 2007 in Bordeaux. More recently, a case was described in Haute-Loire. The investigators are therefore interested today in the emergence of this virus in Limousin following a possible progression through the Massif Central, potentially favored by numerous anti-Covid-19 control containments. The study begins with a computer extraction of patients with Lyme serology from our GLIMS laboratory software (with positive or negative results), a check for non-oppositions. Then the investigators will measure by ELISA in microplates the anti-TBEV IgG as well as the anti-TBEV IgM on the sera + in TBEV IgG. The investigators will then send a patient questionnaire with an information note to document the context of this TBEV seropositivity and to eliminate false-positivities (vaccination). Finally, the investigators will perform PCR on CSF if serum positive and CSF available, followed by an analysis of results. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01031537 -
Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)
|
Phase 2 | |
| Recruiting |
NCT02463942 -
Tick-borne Encephalitis and Positive Borrelial Antibodies
|
N/A | |
| Completed |
NCT01361776 -
Humoral Response to Tick-borne Encephalitis Vaccine in Elderly
|
Phase 2/Phase 3 | |
| Completed |
NCT00161863 -
Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years
|
Phase 3 | |
| Completed |
NCT00161798 -
Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.
|
Phase 2 | |
| Recruiting |
NCT05607394 -
Prevalence of Tick-borne Encephalitis in the Pediatric Population Treated at the HUS and Characterization of Confirmed Pediatric Cases
|
||
| Completed |
NCT01710189 -
Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac
|
Phase 4 | |
| Completed |
NCT00161772 -
Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.
|
Phase 2 | |
| Completed |
NCT00161785 -
Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years
|
Phase 4 | |
| Completed |
NCT00118924 -
Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults
|
Phase 1 | |
| Not yet recruiting |
NCT04573205 -
Primary TBE Vaccination for the Elderly
|
Phase 4 | |
| Completed |
NCT02318069 -
New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly
|
Phase 2/Phase 3 | |
| Completed |
NCT04648241 -
Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older
|
Phase 3 | |
| Completed |
NCT00804219 -
Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination
|
Phase 4 |